Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2010 June;145(3) > Giornale Italiano di Dermatologia e Venereologia 2010 June;145(3):385-91

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,311


eTOC

 

REVIEWS  DERMOPATHOLOGY


Giornale Italiano di Dermatologia e Venereologia 2010 June;145(3):385-91

Copyright © 2010 EDIZIONI MINERVA MEDICA

language: English

Diagnostic tools in Sezary syndrome

Möbs M. 1, Knott M. 2, Fritzen B. 2, Pullmann S. 2, Sterry W. 1, Assaf C. 1, 2

1 Department of Dermatology and Allergy, Skin Cancer Center, Charité Universitätsmedizin, Berlin, Germany; 2 Department of Dermatology, HELIOS Klinikum Krefeld, Krefeld, Germany


PDF  


Primary cutaneous T-cell lymphomas (CTCL) mycosis fungoides (Mf) and Sézary syndrome (SS) belong to the group of non-Hodgkin lymphomas which are characterized by clonally proliferating CD4+ cells localized in the skin. SS is a leukemic variant of CTCL and is characterized by erythroderma, generalized lymphadenopathy, and circulating atypical T-cells with cerebriform nuclei, so-called Sézary cells. Palmoplantar hyperkeratosis, generalized alopecia, and severe pruritus are additional symptoms that are associated with SS. Patients have a poor prognosis with an estimated five year survival of 12.5 to 27 percent and estimated median survival of 14.5 to 18 months. The incidence of MF and also SS has increased with time and may be in part due to improved clinical awareness and especially advances in diagnostic testing.

top of page

Publication History

Cite this article as

Corresponding author e-mail

chalid.assaf@helios-kliniken.de